The claim is documented verbatim in the FDA’s August 2023 warning letter, which quotes the company’s own “Intended Use Chart” (provided to authorized advertisers and posted on teslabiohealing.com) and product labels. Classified testimonial because the company’s own supporting evidence, quoted in the same letter, is uncontrolled user reports (“Based on the trends we have seen with over 20,000 people using Tesla BioHealing technology to date”), not a clinical trial. Classified unreplicated rather than refuted: FDA’s inspection found the devices adulterated (no premarket approval or investigational-device exemption for a device intended to treat these conditions) and misbranded (marketed for uses far beyond the infrared-lamp heating-pad exemption under which they were registered, despite having no heating element), an authoritative regulatory finding that the marketing itself is unlawful, but no source in this case reports a controlled trial that tested and disproved the specific disease claims — the evidentiary status is untested/unsupported rather than affirmatively disproven.